Aptinyx Reports Positive Top-line Data from Phase 2 Study of NYX-2925 in Patients with Fibromyalgia, Demonstrating Significant Effects on Both Biomarkers and Patient-Reported Pain
NYX-2925 demonstrated statistically significant effects on a range of neuroimaging biomarkers and patient-reported outcomes, including pain scores
Neuroimaging biomarkers correlated with patient-reported pain improvements
NYX-2925 was well tolerated with no serious adverse events reported
Conference call today at 8:30 a.m. ET
EVANSTON, Ill., June 10, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformativ...